THE BE T
Multimedia Highlights
From the CardioSource WorldNews YouTube Channel | Scan the QR code to watch the full video
FIRE AND ICE: Cryoballoon vs. Radiofrequency Ablation for Paroxysmal
Atrial Fibrillation
Two Sub-analyses of PEGASUS-TIMI
54: Insights in Particularly High-risk
Populations
Karl-Heinz Kuck, MD, PhD: “The true event
rate at the end of the trial was 35%, so we
were very close to what we had powered the
study for. I therefore think the data from the
study are very realistic, and hopefully we’ll
change clinical practice a little bit over the
next couple of years.”
Michael Crichton, MD: “We’ve seen important subgroup analyses, whether it be with
diabetic patients or patients with PAD, and
that really just reinforces the primary endpoint of PEGASUS. There are important questions to answer for these patients, and we’re
really going after tough, unmet needs and
scientific questions that are supportive of the
overall PEGASUS trial.”
Cover Story Update: Gene Therapy for
the Heart
Tassos Gianakakos, MD: “The way we think
about these cardiovascular diseases is that
we try to subgroup the patients into as small
of groups as the science and the disease
biology dictates. It could be that a patients
suffering from a particular disorder that we’re
designing a therapy for is one of only 50 or
100,000 patients. That’s not typically the way
the drug development community thinks.”
Kuck K-H, Brugada J, Fürnkranz, A, et al.
N Engl J Med. 2016;374:2235-45.
DYSIS and DYSIS II: LDL Levels in Patients on Chronic Statin Therapy
NCDR: Wide Variation in Hospital Use
of Early Catheterization for NSTEMI
A Polymer-free Drug-Filled Stent: The
RevElution Trial
Andrew Tershakovec, MD: “It’s about
identifying the patient s and getting them on
therapy. It’s about evaluating if the treatment
is effective as it could be. Do you need to
optimize the treatment in some way? It’s also
about checking in with patient compliance,
because this is a lifelong problem. It’s not
something where you can take the medicine
for 6 months and then say, ‘OK, now I’m
going to stop.’”
Carolina Hansen, MD: As we get more used
to using guidelines as guidance for patient
treatment, and as we are more aware of
these differences, I hope these studies will
help physicians stick more to the guidelines.
Stephen Worthley, MD: This confirms
what we’ve seen in many of that early
preclinical work. We’ve seen a lot of early
healing at 1 month; we’ve seen very low
neointimal proliferation; we’ve seen very low
malapposition [...]. It’s early days and it’s 1
month, but it’s the complete dataset on the
OCT substudy, and it’s very exciting.
14
CardioSource WorldNews
August 2016